Integris Health, a leading medical devices company, has raised primary capital from a consortium of prominent investors, including Mukul Agarwal and the India SME Fund. The company, already backed by Everstone Capital, plans to use the funds to expand into new therapeutic areas such as in-vitro diagnostics and laboratory solutions. This expansion will be driven by strategic acquisitions and in-house product development, according to a company press release.
In a pivotal leadership move, Integris Health appointed Probir Das as CEO in 2024 to spearhead its growth strategy. The company is gearing up for an initial public offering (IPO) by the end of 2025, with IPO preparations already underway.
Founded in 2008 by Gurmit Singh Chugh, Integris Health operates in interventional cardiology, cardiovascular, and vascular surgery. The company boasts a fully integrated business model encompassing product development, manufacturing, and global sales. Its manufacturing facilities are located in Germany, the Netherlands, and India, with a sales network spanning over 50 markets worldwide.
Over the years, Integris Health has forged strategic partnerships with hospitals, engineering institutes, global med-tech companies, and interventional cardiologists. The company integrates German engineering, intellectual property, and high-quality standards with India’s entrepreneurial culture and cost-effective manufacturing capabilities to produce innovative yet affordable medical devices.
With a focus on empowering India’s med-tech industry, Integris Health continues to leverage its cutting-edge R&D, robust distribution network, and strategic alliances to deliver high-quality solutions. The latest funding will enable the company to further solidify its position in the global med-tech market and accelerate its growth trajectory.
